Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. More Details
+ 1 more risk
Mediocre balance sheet with questionable track record.
Share Price & News
How has Accuray's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ARAY's weekly volatility (10%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ARAY exceeded the US Medical Equipment industry which returned 16.3% over the past year.
Return vs Market: ARAY exceeded the US Market which returned 19.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Accuray's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat We Learned About Accuray's (NASDAQ:ARAY) CEO Compensation
3 months ago | Simply Wall StHow Much Did Accuray's(NASDAQ:ARAY) Shareholders Earn From Share Price Movements Over The Last Five Years?
3 months ago | Simply Wall StAccuray (NASDAQ:ARAY) Share Prices Have Dropped 55% In The Last Five Years
Is Accuray undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ARAY ($4.36) is trading above our estimate of fair value ($3.45)
Significantly Below Fair Value: ARAY is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ARAY is good value based on its PE Ratio (29x) compared to the US Medical Equipment industry average (48.6x).
PE vs Market: ARAY is poor value based on its PE Ratio (29x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: ARAY's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ARAY is overvalued based on its PB Ratio (5.9x) compared to the US Medical Equipment industry average (4.4x).
How is Accuray forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARAY's earnings are forecast to decline over the next 3 years (-74.3% per year).
Earnings vs Market: ARAY's earnings are forecast to decline over the next 3 years (-74.3% per year).
High Growth Earnings: ARAY's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ARAY's revenue (8.6% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: ARAY's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARAY's Return on Equity is forecast to be high in 3 years time
How has Accuray performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARAY has a large one-off gain of $13.0M impacting its September 30 2020 financial results.
Growing Profit Margin: ARAY became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ARAY has become profitable over the past 5 years, growing earnings by 31.9% per year.
Accelerating Growth: ARAY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ARAY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: Whilst ARAY's Return on Equity (20.14%) is high, this metric is skewed due to their high level of debt.
How is Accuray's financial position?
Financial Position Analysis
Short Term Liabilities: ARAY's short term assets ($332.5M) exceed its short term liabilities ($169.1M).
Long Term Liabilities: ARAY's short term assets ($332.5M) exceed its long term liabilities ($228.2M).
Debt to Equity History and Analysis
Debt Level: ARAY's debt to equity ratio (266.4%) is considered high.
Reducing Debt: ARAY's debt to equity ratio has reduced from 319.7% to 266.4% over the past 5 years.
Debt Coverage: ARAY's debt is not well covered by operating cash flow (11.3%).
Interest Coverage: ARAY's interest payments on its debt are not well covered by EBIT (1.2x coverage).
What is Accuray current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARAY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joshua Levine (62 yo)
Mr. Joshua H. Levine, also known as Josh, has been an Independent Director of Natus Medical Inc. since June 22, 2018. He has been the Chief Executive Officer and President at Accuray Incorporated since Oct...
CEO Compensation Analysis
Compensation vs Market: Joshua's total compensation ($USD2.91M) is above average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Joshua's compensation has been consistent with company performance over the past year.
|Senior VP & CFO||2.08yrs||US$880.87k||0.091% |
|Senior VP & Chief Administrative Officer||2.08yrs||US$673.51k||0.033% |
|Senior VP||2.08yrs||US$683.41k||0.043% |
|Chief Commercial Officer and Senior VP of R&D||1.08yrs||US$1.95m||0.38% |
|Senior Vice President of Global Operations||0.75yr||no data||0.14% |
|Vice President of Finance & Investor Relations||no data||no data||no data|
|Public Relations Director||6.42yrs||no data||no data|
|Senior Vice President of Global Service||1.83yrs||no data||no data|
|Senior Vice President of Global Quality & Regulatory Affairs||no data||no data||no data|
|Senior Director of Patient Access||no data||no data||no data|
|Vice President of Product Strategy||no data||no data||no data|
Experienced Management: ARAY's management team is considered experienced (2.1 years average tenure).
|Independent Director||2.33yrs||US$227.50k||0.21% |
|Independent Chairman||10.58yrs||US$241.07k||0.22% |
|Independent Director||1.17yrs||US$226.12k||0.0099% |
|Independent Vice Chairperson||12.17yrs||US$220.00k||0.16% |
|Independent Director||10.5yrs||US$210.31k||0.15% |
|Independent Director||2.83yrs||US$210.45k||0.055% |
|Independent Director||8.5yrs||US$212.50k||0.12% |
|Independent Director||0.33yr||no data||no data|
Experienced Board: ARAY's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARAY insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Accuray Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Accuray Incorporated
- Ticker: ARAY
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$397.953m
- Shares outstanding: 91.27m
- Website: https://www.accuray.com
Number of Employees
- Accuray Incorporated
- 1310 Chesapeake Terrace
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARAY||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2007|
|XEJ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2007|
|0H8I||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 2007|
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 00:23|
|End of Day Share Price||2020/11/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.